SIRT1-modified human umbilical cord mesenchymal stem cells ameliorate experimental peritoneal fibrosis by inhibiting the TGF-β/Smad3 pathway

被引：17

作者：

Guo, Yanhong ^{[2
]}

Wang, Liuwei ^{[2
]}

Gou, Rong ^{[2
]}

Wang, Yulin ^{[2
]}

Shi, Xiujie ^{[1
]}

Pang, Xinxin ^{[1
]}

Tang, Lin ^{[2
]}

机构：

[1] Henan Univ Chinese Med, Hosp Affiliated 2, Henan Prov Hosp Tradit Chinese Med, Dept Nephropathy, 6 Dong Feng Rd, Zhengzhou 450002, Henan, Peoples R China

[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Nephropathy, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China

来源：

STEM CELL RESEARCH & THERAPY | 2020年 / 11卷 / 01期

关键词：

Peritoneal fibrosis; SIRT1; hUCMSCs; EMT; TGF-beta; PLATELET-RICH PLASMA; CARDIAC FIBROSIS; LIVER FIBROSIS; ACTIVATION; PROTECTS; HEALTH;

D O I：

10.1186/s13287-020-01878-2

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Introduction: Peritoneal fibrosis is a serious complication of long-term peritoneal dialysis (PD). Combination therapies are emerging as a promising treatment for tissue damage. Here, we investigated the therapeutic potential of SIRT1-modified human umbilical cord mesenchymal stem cells (hUCMSCs) for peritoneal fibrosis. Methods: SIRT1 was overexpressed in hUCMSCs to establish SIRT1-modified hUCMSCs. Co-culture and transplantation experiments were performed in TGF-beta-stimulated Met-5A cells and peritoneal damage rodent model to assess the therapeutic potential of SIRT1-modified hUCMSCs for peritoneal fibrosis through qPCR, Western blot, and peritoneal function analyses. Results: SIRT1-modified hUCMSC administration had more potent anti-fibrosis ability than hUCMSCs, which significantly inhibited the expression of fibrotic genes and suppressed EMT process, increased ultrafiltration volume, and restored homeostasis of bioincompatible factors in dialysis solution. Mechanistically, SIRT1-modified hUCMSCs attenuated peritoneal fibrosis through reducing peritoneal inflammation and inhibiting the TGF-beta/Smad3 pathway in peritoneal omentum tissues. Conclusion: SIRT1-modified hUCMSCs might work as a promising therapeutic strategy for the treatment of peritoneal dialysis-induced peritoneal damage and fibrosis.

引用

页数：12

共 43 条

[1]

Aguilera Abelardo, 2005, Curr Opin Investig Drugs, V6, P262

[2] Alternative activation of macrophages in human peritoneum: implications for peritoneal fibrosis [J].